Tony Mok

发表

Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell, 2015, Nature Reviews Disease Primers.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Federico Cappuzzo, Paul Delmar, Tudor Ciuleanu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

T. Mok, Jin-Ji Yang, Tony Mok, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Koichi Goto, Masahiro Fukuoka, Nobuyuki Yamamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

PARP inhibition in BRCA-mutated breast and ovarian cancers

T. Mok, Tony Mok, Stephen L Chan, 2010, The Lancet.

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Luca Toschi, A. Iafrate, P. Jänne, 2010, Cancer cell.

Management of non-small-cell lung cancer: recent developments

K. Rabe, T. Mok, J. Soria, 2013, The Lancet.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Scott M Lippman, Jean-Yves Douillard, 2008, The Lancet.

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017, The New England journal of medicine.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Li Zhang, Hongming Pan, Chong-Jen Yu, 2013, The Lancet. Oncology.

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Mayumi Ono, Jose Luis Mate, David Jablons, 2005, Clinical Cancer Research.